31733-59-2Relevant academic research and scientific papers
Pharmaceutical composition and method of treating cancer
-
Page/Page column 45-46, (2020/12/07)
Cytotoxic compounds containing a phenyl core, amide link(s), an imidazolinone or a propenamide moiety. Also described are pharmaceutical compositions incorporating the cytotoxic compounds and methods for treating cancer. These compounds are cytotoxic against breast, prostate, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
2-Furanylboronic acid as an effective catalyst for the direct amidation of carboxylic acids at room temperature
Tam, Eric Kwok Wai,Rita,Liu, Lionel Yiqian,Chen, Anqi
, p. 1100 - 1107 (2015/02/19)
2-Furanylboronic acid has been identified as an inexpensive and effective catalyst for the dehydrative amide formation of carboxylic acids and amines. This transformation can be efficiently carried out at room temperature and is applicable to a wide range of carboxylic acids with primary and secondary amines to afford amides in good to excellent yields.
Anticonvulsant activity of some 4-aminophenylacetamides
Clark,Davenport
, p. 18 - 20 (2007/10/02)
A series of 4-aminophenylacetamides was prepared and evaluated for anticonsulvant activity. These compounds were prepared during studies designed to determine the relationship between benzamide-like compounds and anticonsulvant effects. Unlike benzamides, these phenylacetamides have a methylene group between the aromatic ring and the amide carbonyl. Consequently, formal conjugation is lost, and the number of conformational degrees of freedom has increased. The compounds were tested in mice against seizures induced by electroshock and pentylenetetrazol, and in the rotorod assay for neurologic deficit. The more active and selective anticonsulvants prepared in this study were those having an additional aromatic ring as part of the substituent on the amide nitrogen. Compound 16, the 4-aminophenylacetamide derived from 2,6-dimethylaniline, was the most potent compound observed (ED50 = 50.50 mg/kg against electroshock-induced convulsions and ED50 = 93.20 mg/kg against pentylenetetrazol-induced convulsions).
